Clinical trials
Hematologic Neoplasms trials in the United Kingdom
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
70 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2002 | 1 |
| 2006 | 2 |
| 2007 | 3 |
| 2008 | 1 |
| 2009 | 3 |
| 2010 | 1 |
| 2011 | 7 |
| 2012 | 3 |
| 2013 | 3 |
| 2014 | 2 |
| 2015 | 4 |
| 2016 | 2 |
| 2017 | 2 |
| 2018 | 1 |
| 2019 | 3 |
| 2020 | 5 |
| 2021 | 5 |
| 2022 | 2 |
| 2023 | 7 |
| 2024 | 4 |
| 2025 | 4 |
| 2026 | 5 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 29 |
| Recruiting | 19 |
| Terminated | 8 |
| Active, not recruiting | 6 |
| Unknown status | 3 |
| Not yet recruiting | 2 |
| Withdrawn | 2 |
| Enrolling by invitation | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Cancer Research UK | 8 |
| Kiadis Pharma | 5 |
| Bristol-Myers Squibb | 3 |
| Celgene | 3 |
| Imperial College London | 3 |
| Novartis Pharmaceuticals | 3 |
| AbbVie | 2 |
| Amgen | 2 |
| AstraZeneca | 2 |
| Janssen Research & Development, LLC | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Hematologic Neoplasms | 70 |
| Neoplasms | 22 |
| Leukemia, Myeloid, Acute | 14 |
| Myelodysplastic Syndromes | 12 |
| Leukemia | 10 |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 8 |
| Multiple Myeloma | 7 |
| Neoplasms by Site | 7 |
| Lymphoma | 6 |
| Neoplasms by Histologic Type | 6 |
Trials
Showing 1 to 25 of 70. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.